Healthcare provider profile · identity verified

Mary Beth Murphy, MD

Family Practice · ALBUQUERQUE, NM · NPI 1265953319

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	374	116
Atorvastatin Calcium	Atorvastatin Calcium	365	125
Gabapentin	Gabapentin	305	76
Levothyroxine Sodium	Levothyroxine Sodium	235	75
Amlodipine Besylate	Amlodipine Besylate	204	65
Albuterol Sulfate Hfa	Albuterol Sulfate	158	52
Losartan Potassium	Losartan Potassium	157	50
Omeprazole	Omeprazole	157	47
Oxycodone Hcl	Oxycodone Hcl	156	22
Hydrochlorothiazide	Hydrochlorothiazide	153	49
Metformin Hcl	Metformin Hcl	122	46
Sertraline Hcl	Sertraline Hcl	96	33
Trazodone Hcl	Trazodone Hcl	95	25
Glipizide	Glipizide	81	18
Hydroxyzine Hcl	Hydroxyzine Hcl	79	20
Fluticasone Propionate	Fluticasone Propionate	76	31
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	74	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	74	18
Tamsulosin Hcl	Tamsulosin Hcl	71	26
Metformin Hcl Er	Metformin Hcl	69	18
Carvedilol	Carvedilol	62	19
Trulicity	Dulaglutide	60	15
Buspirone Hcl	Buspirone Hcl	59	14
Tramadol Hcl	Tramadol Hcl	59	suppressed
Famotidine	Famotidine	58	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	58	18
Mirtazapine	Mirtazapine	57	16
Baclofen	Baclofen	55	18
Fluoxetine Hcl	Fluoxetine Hcl	55	18
Metoprolol Succinate	Metoprolol Succinate	54	18
Ibuprofen	Ibuprofen	49	20
Furosemide	Furosemide	46	16
Tizanidine Hcl	Tizanidine Hcl	45	11
Pantoprazole Sodium	Pantoprazole Sodium	42	15
Bupropion Xl	Bupropion Hcl	41	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	40	suppressed
Finasteride	Finasteride	39	15
Rosuvastatin Calcium	Rosuvastatin Calcium	39	14
Metoprolol Tartrate	Metoprolol Tartrate	38	12
Oxybutynin Chloride Er	Oxybutynin Chloride	38	suppressed
Duloxetine Hcl	Duloxetine Hcl	36	13
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	13
Montelukast Sodium	Montelukast Sodium	33	13
Quetiapine Fumarate	Quetiapine Fumarate	33	suppressed
Simvastatin	Simvastatin	31	11
Glipizide Er	Glipizide	30	suppressed
Acyclovir	Acyclovir	28	suppressed
Alprazolam	Alprazolam	28	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	28	suppressed
Meloxicam	Meloxicam	28	11
Myrbetriq	Mirabegron	28	suppressed
Clonidine Hcl	Clonidine Hcl	27	suppressed
Lovastatin	Lovastatin	27	suppressed
Methocarbamol	Methocarbamol	27	11
Arnuity Ellipta	Fluticasone Furoate	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Lorazepam	Lorazepam	24	suppressed
Chlorthalidone	Chlorthalidone	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Risperidone	Risperidone	22	suppressed
Allopurinol	Allopurinol	21	suppressed
Aripiprazole	Aripiprazole	20	suppressed
Prednisone	Prednisone	20	15
Clonazepam	Clonazepam	19	suppressed
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Armour Thyroid	Thyroid,pork	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Jardiance	Empagliflozin	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	18	suppressed
Glimepiride	Glimepiride	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	11
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Topiramate	Topiramate	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	16	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Eliquis	Apixaban	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Humalog Kwikpen U-100	Insulin Lispro	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Clotrimazole	Clotrimazole	14	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Divalproex Sodium Er	Divalproex Sodium	13	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	suppressed
Erythromycin	Erythromycin Base	13	suppressed
Ibu	Ibuprofen	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Bupropion Hcl	Bupropion Hcl	11	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	11	suppressed
Potassium Chloride	Potassium Chloride	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error